Skip to content

Using Vibroacoustic Therapy in a Patient With Co-infection and COVID-19

Complex Treatment Using Vibroacoustic Therapy in a Patient With Co-infection and COVID-19: Case Report.

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05188482
Enrollment
1
Registered
2022-01-12
Start date
2020-09-29
Completion date
2021-01-01
Last updated
2022-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

SARS CoV 2 Infection

Keywords

periprosthetic joint infection, SARS-CoV-2, co-infections, case report., vibroacoustic therapy

Brief summary

This article describes a case of successful treatment of a 59-year-old man with sepsis as a result of periprosthetic infection against the background of severe SARS-CoV-2-19, who was hospitalized for 59 days, 57 of which were in the intensive care unit. Vibroacoustic pulmonary therapy, the concept of noninvasive ventilation, syndrome therapy, combination antibiotic therapy taking into account the pathogen and antibiotic sensitivity were used in the treatment.

Detailed description

During the pandemic caused by SARS-CoV-2-19, the whole world faced difficulties. Nevertheless, surgeons had to perform surgical treatment for patients who needed immediate help with a confirmed coronavirus infection \[1, 2, 3\]. Periprosthetic joint infection is a severe and undesirable consequence after arthroplasty \[4, 5\]. Patients with coronavirus infection and bacterial infection correlate with an unfavorable outcome \[6, 7, 8\] The effect of vibroacoustic therapy in the treatment of various conditions has not been sufficiently studied \[9, 10\]. This clinical case describes the complex therapy of a patient with a periprosthetic infection on the background of SARS-CoV-2 using a vibroacoustic pulmonary device.

Interventions

Vibroacoustic respiratory therapy

Sponsors

Astana Medical University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
MALE
Age
59 Years to 59 Years

Inclusion criteria

* P/F less 300 torr * COVID-19 Virus Infection

Exclusion criteria

* children * acute stroke * acute coronary syndrome * DVT * implanted pacemaker * rib fracture * infection on chest

Design outcomes

Primary

MeasureTime frameDescription
Change of time spent on ventilation1-2 daysChanging of the time spent by patients on mechanical ventilation

Countries

Kazakhstan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026